Corvus Pharmaceuticals Inc (CRVS)

03:27 AM

What analysts say about Corvus Pharmaceuticals Inc. stockStrongest growth potential - Autocar Professional

03:27 AM

Jul 22, 2025

Corvus Pharmaceuticals Inc. Stock Analysis and ForecastUnstoppable investment returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What drives Corvus Pharmaceuticals Inc. stock priceUnmatched market performance - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is Corvus Pharmaceuticals Inc. a good long term investmentUnstoppable trading performance - jammulinksnews.com

Jul 22, 2025

Jul 15, 2025

Why Corvus Pharmaceuticals Inc. stock attracts strong analyst attentionReal Time Alert Service - Newser

Jul 15, 2025

Jul 15, 2025

What makes Corvus Pharmaceuticals Inc. stock price move sharplyDouble Your Capital Alerts - Newser

Jul 15, 2025

Jul 15, 2025

How Corvus Pharmaceuticals Inc. stock performs during market volatilityDaily Breakout Picks - Newser

Jul 15, 2025

Jul 08, 2025

Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says - MarketScreener

Jul 08, 2025

Jul 03, 2025

Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis - TipRanks

Jul 03, 2025

Jul 02, 2025

Corvus Pharmaceuticals: Insider Confidence and Clinical Catalysts Fueling Growth - AInvest

Jul 02, 2025

Jul 01, 2025

OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million By Investing.com - Investing.com Canada

Jul 01, 2025

Jun 30, 2025

Corvus Pharmaceuticals, Inc.(NasdaqGM: CRVS) added to Russell 3000 Index - MarketScreener

Jun 30, 2025

Jun 25, 2025

Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News - GuruFocus

Jun 25, 2025

Jun 25, 2025

Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan

Jun 25, 2025

Jun 18, 2025

Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX

Jun 18, 2025

Jun 13, 2025

Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha

Jun 13, 2025

Jun 13, 2025

Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 13, 2025

Jun 11, 2025

Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan

Jun 11, 2025

Jun 11, 2025

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView

Jun 11, 2025

Jun 10, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jun 10, 2025

Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa

Jun 04, 2025

Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq

Jun 04, 2025

Jun 04, 2025

Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener

Jun 04, 2025

Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia

Jun 04, 2025

Jun 04, 2025

Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus

Jun 04, 2025

Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com

Jun 04, 2025

Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire

Jun 04, 2025

May 28, 2025

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 28, 2025

May 28, 2025

Exclusive: Corvus Pharmaceuticals Reveals Latest Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025

May 20, 2025

Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN

May 20, 2025

May 20, 2025

CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 20, 2025

May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus

May 20, 2025

May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus

May 20, 2025

May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India

May 20, 2025

May 20, 2025

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com

May 20, 2025

May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating - Investing.com

May 20, 2025

May 13, 2025

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World

May 13, 2025

May 12, 2025

Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus

May 12, 2025